Effect of Lactobacillus GG on gut permeability and microbiome in VLBW neonates
GG 乳杆菌对 VLBW 新生儿肠道通透性和微生物组的影响
基本信息
- 批准号:8321489
- 负责人:
- 金额:$ 30.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAftercareBacteriaBacterial TranslocationBiological MarkersBirth WeightClinical TrialsClinical Trials DesignColony-forming unitsDataDevelopmentDiseaseDoseDrug FormulationsElementsEmergency SituationEquilibriumFDA approvedFunctional disorderFutureGoalsGrowthIncidenceInfantInflammatory ResponseInterventionIntestinesLactobacillusLactobacillus casei rhamnosusLactuloseLeadLifeMannitolMeasurementMeasuresModificationMonitorMorbidity - disease rateNecrosisNecrotizing EnterocolitisNeonatal Intensive CareNeurodevelopmental ImpairmentOperative Surgical ProceduresOral AdministrationPathogenesisPermeabilityPhasePlayPopulationPredispositionPreparationPreventionPreventiveProbioticsProteinsRandomizedRandomized Clinical TrialsRegimenReportingRiskRoleSafetySerumShort Bowel SyndromeSpecific qualifier valueSurvivorsTight JunctionsTimeTrypsinUrineVery Low Birth Weight Infantburden of illnesscohortcostdesignefficacy testingefficacy trialexperiencegastrointestinalgut microbiotahigh riskhigh risk infantimprovedin vivolong term hospitalizationmicrobialmicrobiomemicroorganismmortalityneonatenovelopen labelprematurepreventrRNA Genestherapy durationzonulin
项目摘要
DESCRIPTION (provided by applicant): Necrotizing enterocolitis (NEC) is a life-threatening, gastrointestinal emergency that occurs in 7 to 10% very low birth weight (VLBW, <1500 g) infants. Despite improvements in neonatal intensive care, the birth weight-specific incidence of NEC has not changed over the past 2 decades. However, the total burden of disease is increasing due to increased survival of very immature infants. Mortality remains high and survivors experience significant morbidity including post-surgical short bowel syndrome, poor growth, prolonged hospitalization, and long-term neurodevelopmental impairments. Prematurity, gut dysbiosis, and impaired intestinal barrier function are three key factors in NEC pathogenesis. The co-existence of these three factors leads to bacterial translocation across an impaired intestinal mucosal barrier, intense local and systemic inflammatory responses, and intestinal necrosis typical of NEC. To mitigate the risk of NEC, the use of probiotics has been proposed to correct the intestinal barrier dysfunction and improve gut dysbiosis. Although there was a 30% reduction in NEC incidence in multiple randomized clinical trials of probiotics to prevent NEC, various formulations, doses, and duration of therapy were used, infants <1000 g BW with the highest NEC incidence were underrepresented, and no FDA-approved products are available to assure quality and safety under good manufacturing practices. There is an urgent need for well-designed trials with proper regulatory oversight to address the dose of a specified probiotic product, in a high-risk, well characterized, population. Our long-term goal is to determine the safety and efficacy of Lactobacillus rhamnosus GG (LGG) to prevent NEC in VLBW infants. The overall objective of the current proposal is to conduct an open label, safety and pilot dose escalation study of LGG to collect information needed to design Phase III safety and efficacy trials of LGG in the preterm population. Specifically, the proposed study will assess the utility of an easily collected novel biomarker zonulin to monitor intestinal permeability, and provide information on the safety and acceptability of administering 3 different doses of LGG to VLBW infants, the optimal dose of LGG to improve intestinal barrier function, and the impact of LGG on GI microbiota. The specific aims will address the central hypotheses that 1) increased levels of biomarkers (serum zonulin, Lactulose/Mannitol urine ratio, and/or fecal a-1 anti-trypsin) will identify infants with increased intestinal permeability; and 2) oral administration of LGG in VLBW infants with elevated intestinal permeability biomarkers will improve gut barrier function and favor the establishment of a beneficial gut microbiota. Development of biomarkers to identify infants with increased intestinal permeability who are at high risk for NEC will facilitate clinical trials of potential preventive therapies. Probiotic therapy is a promising, low-cost, and likely safe intervention to reduce intestinal permeability in high-risk infants. The data generated from the proposed studies will directly lead to decisions concerning future randomized safety and efficacy trials of LGG to prevent NEC in the preterm population.
描述(由申请人提供):坏死性小肠结肠炎(NEC)是一种危及生命的胃肠道急症,发生在7 - 10%的极低出生体重(VLBW,<1500 g)婴儿中。尽管新生儿重症监护有所改善,但出生体重特异性NEC发病率在过去20年中没有改变。然而,由于极不成熟婴儿的存活率增加,疾病的总负担正在增加。死亡率仍然很高,幸存者经历了显著的发病率,包括手术后短肠综合征,生长不良,住院时间延长和长期神经发育障碍。早产、肠道生态失调和肠屏障功能受损是NEC发病的三个关键因素。这三种因素的共存导致细菌移位穿过受损的肠粘膜屏障、强烈的局部和全身炎症反应以及NEC典型的肠坏死。为了减轻NEC的风险,已经提出使用益生菌来纠正肠道屏障功能障碍并改善肠道生态失调。尽管在多项预防NEC的益生菌随机临床试验中NEC发生率降低了30%,但使用了各种配方,剂量和治疗持续时间,具有最高NEC发生率的<1000 g BW的婴儿代表性不足,并且没有FDA批准的产品可用于确保良好生产规范下的质量和安全性。迫切需要设计良好的试验,并进行适当的监管监督,以解决特定益生菌产品在高风险,良好特征人群中的剂量问题。我们的长期目标是确定鼠李糖乳杆菌GG(LGG)预防极低出生体重婴儿NEC的安全性和有效性。当前提案的总体目标是进行一项LGG的开放标签、安全性和初步剂量递增研究,以收集设计早产儿人群中LGG III期安全性和疗效试验所需的信息。具体而言,拟议的研究将评估一种易于收集的新型生物标志物zonulin监测肠道通透性的效用,并提供有关VLBW婴儿给予3种不同剂量LGG的安全性和可接受性的信息,LGG改善肠道屏障功能的最佳剂量,以及LGG对GI微生物群的影响。具体目标将解决以下中心假设:1)生物标志物(血清zonulin、乳果糖/甘露糖尿比和/或粪便α-1抗胰蛋白酶)水平升高将识别肠通透性增加的婴儿; 2)肠通透性生物标志物升高的VLBW婴儿口服LGG将改善肠道屏障功能并有利于建立有益的肠道微生物群。 开发生物标志物来识别肠通透性增加的NEC高危婴儿,将促进潜在预防性治疗的临床试验。益生菌治疗是一种有前途的,低成本的,可能安全的干预措施,以减少高危婴儿的肠道通透性。拟议研究产生的数据将直接导致未来LGG预防早产儿人群NEC的随机安全性和有效性试验的决策。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alessio Fasano其他文献
Alessio Fasano的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alessio Fasano', 18)}}的其他基金
The Celiac Disease Genomic, Environmental, Microbiome, and Metabolomic (CD-GEMM) Prospective Cohort Study
乳糜泻基因组、环境、微生物组和代谢组 (CD-GEMM) 前瞻性队列研究
- 批准号:
10905694 - 财政年份:2023
- 资助金额:
$ 30.39万 - 项目类别:
Microbiome-derived Metabolites Linked to Celiac Disease Onset in Infants at Risk
微生物组衍生的代谢物与高危婴儿乳糜泻的发病有关
- 批准号:
9766265 - 财政年份:2016
- 资助金额:
$ 30.39万 - 项目类别:
The Celiac Disease Genome, Environment, Microbiome, and Metabolome (CD-GEMM) prospective cohort study
乳糜泻基因组、环境、微生物组和代谢组 (CD-GEMM) 前瞻性队列研究
- 批准号:
10474123 - 财政年份:2016
- 资助金额:
$ 30.39万 - 项目类别:
Effect of Lactobacillus GG on gut permeability and microbiome in VLBW neonates
GG 乳杆菌对 VLBW 新生儿肠道通透性和微生物组的影响
- 批准号:
8206095 - 财政年份:2011
- 资助金额:
$ 30.39万 - 项目类别:
Effect of Lactobacillus GG on gut permeability and microbiome in VLBW neonates
GG 乳杆菌对 VLBW 新生儿肠道通透性和微生物组的影响
- 批准号:
8536214 - 财政年份:2011
- 资助金额:
$ 30.39万 - 项目类别:
Intestinal Mucosal Immune and Functional Response to Gastric and Enteric Pathogen
对胃肠道病原体的肠粘膜免疫和功能反应
- 批准号:
7701565 - 财政年份:2009
- 资助金额:
$ 30.39万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 30.39万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 30.39万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 30.39万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 30.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




